Analysis of whether tazetostat (Daveco) is a targeted drug and its mechanism of action

Tazemetostat (Tazemetostat) is a new type of oral small molecule drug that belongs to the category of targeted drugs. It mainly targets the inhibition of the EZH2 enzyme (Enhancer of Zeste Homolog 2) in epigenetics. EZH2 is abnormally highly expressed in a variety of tumor cells and is an important driver of cancer cell proliferation and tumorigenesis. Therefore, tazerestat achieves intervention in specific tumor types by precisely acting on this molecular target, which is different from the broad-spectrum killing mode of traditional chemotherapy drugs.

In terms of specific mechanism of action, tazerestat can selectively inhibit the methyltransferase activity of EZH2 and block H3K27 trimethylation (H3K27me3) modification. This modification silences the expression of tumor suppressor genes in tumor cells, and inhibiting EZH2 can restore the activity of these genes, thereby inhibiting tumor growth, inducing cancer cell apoptosis, and slowing down disease progression. In addition, tazerestat has higher selectivity for EZH2 mutant tumors, making the treatment more precise and the side effects relatively controllable.

In clinical application, tazerestat is mainly used in patients with relapsed or refractory follicular lymphoma and certain solid tumors. Compared with traditional chemotherapy, it can reduce damage to normal cells and improve the stability of the efficacy by targeting the core signaling pathways of tumors. During treatment, patients can take medication orally, which also improves medication convenience and compliance.

In general, tazerestat is a typical targeted drug that intervenes in the key mechanisms of tumor occurrence and development by precisely inhibiting EZH2 activity to achieve effective control of specific tumor types. Compared with chemotherapy, its effect is more precise and its side effects are relatively controllable. It is suitable for patients with abnormal expression or mutation of EZH2, providing a new option in the field of targeted therapy.

Reference materials:https://www.drugs.com/